Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 14/20 | 0.45 |
| ▸ | DRD2 | P14416 | 9/20 | 0.42 |
| ▸ | DRD4 | P21917 | 5/20 | 0.42 |
| ▸ | DRD3 | P35462 | 4/20 | 0.42 |
| ▸ | DRD1 | P21728 | 6/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 5/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840312 | 1.00 | CHRM1 (0.45) | CHRM1DRD2DRD4DRD3DRD1 | |
| SCHEMBL4840330 | 1.00 | CHRM1 (0.45) | CHRM1DRD2DRD4DRD3DRD1 | |
| SCHEMBL4843041 | 0.95 | CHRM1 (0.44) | CHRM1DRD2DRD4DRD3DRD1 | |
| SCHEMBL4843061 | 0.95 | CHRM1 (0.44) | CHRM1DRD2DRD4DRD3DRD1 | |
| SCHEMBL4843053 | 0.95 | CHRM1 (0.44) | CHRM1DRD2DRD4DRD3DRD1 | |
| SCHEMBL4846422 | 0.90 | CHRM1 (0.47) | CHRM1DRD2DRD1HRH1PAK1 | |
| SCHEMBL14163677 | 0.90 | DRD2 (0.46) | CHRM1DRD2DRD4DRD3DRD1 | |
| SCHEMBL4846434 | 0.90 | CHRM1 (0.47) | CHRM1DRD2DRD1HRH1PAK1 | |
| SCHEMBL4846426 | 0.90 | CHRM1 (0.47) | CHRM1DRD2DRD1HRH1PAK1 | |
| SCHEMBL4843260 | 0.89 | CHRM1 (0.40) | CHRM1DRD2DRD4DRD3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546134-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | ELI LILLY AND COMPANY (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2004014895-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | claimed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY | 2006-04-20 | — | — | US | disclosed |
| EP-1546134-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | ELI LILLY AND COMPANY (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004014895-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | GABBR1, GABBR2, GABRA5 | CHRM1 302/4885DRD2 7/4885DRD4 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.